Murray R G
Department of Cardiology, East Birmingham District General Hospital, United-Kingdom.
Arch Mal Coeur Vaiss. 1990 Feb;83 Spec No 1:37-40.
Thrombolytic therapy has been one of the most important advances in the field of cardiovascular medicine. Several agents are available and research is continuing to develop new effective thrombolytics with a rapid onset of action. The efficacy of thrombolytic therapy can be evaluated by a number of criteria such as the reperfusion time, the incidence of coronary recanalisation, left ventricular function, and survival. Survival is certainly the parameter of choice for assessing any thrombolytic protocol. The aim of this paper is therefore to review the results of survival studies with Eminase, one of the new thrombolytic agents used in the treatment of acute myocardial infarction.
溶栓治疗一直是心血管医学领域最重要的进展之一。有几种药物可供使用，并且研究仍在继续开发起效迅速的新型有效溶栓剂。溶栓治疗的疗效可以通过多种标准来评估，如再灌注时间、冠状动脉再通发生率、左心室功能和生存率。生存率无疑是评估任何溶栓方案的首选参数。因此，本文的目的是综述使用Eminase（一种用于治疗急性心肌梗死的新型溶栓剂）的生存研究结果。
